Medix Biochemica, a global leader in the supply of critical raw materials to the in vitro diagnostics industry, has acquired 100% of the shares of ViroStat.
As a result of the partnership, Medix Biochemica will be able to provide its customers with market-leading infectious disease antibodies and antigens for their IVD immunoassay test development.
ViroStat operations will remain in Westbrook, Maine, and its employees – including President Dr. Douglas McAllister and General Manager Duncan McAllister – will join Medix Biochemica following the acquisition.
Founded in 1985 by Dr Douglas McAllister, ViroStat is a globally leading primary manufacturer of high-quality antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens.
For example, the company is widely known for its high affinity antibodies to Influenza A, Influenza B, RSV and Strep A for use in rapid lateral flow devices. ViroStat is headquartered and has its production site in Westbrook (Maine, US).
"We are very excited to welcome the whole ViroStat team to Medix Biochemica," says Steve Ferguson, CEO of Medix Biochemica.
"The partnership with ViroStat provides Medix Biochemica with market-leading products for broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens."
"There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan and the whole ViroStat team have built over the last 38 years."
"I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally".
Douglas McAllister, President of ViroStat notes that "partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios."
"ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavours to stay ahead of new and emerging pathogens."
"We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit."
